Only a few case reports have described the use of the B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitor vemurafenib during pregnancy (14–17); however, to the best of our knowledge, the present study is the first report documenting combined BRAF and mitogen-activated protein kinase kinase (MEK) inhibition with dabrafenib and trametinib (D + T) in a pregnant patient with melanoma brain MTS. Here, MAP2K7 is linked to melanoma.